Abstract
Ewing sarcoma (ES), a highly malignant pediatric tumor, is consistently associated with translocations that fuse the EWS gene with a member of the ETS family gene, most commonly FLI-1. Despite significant advances with multiagent chemotherapy, surgery and radiotherapy, about 40% of ES patients still die from the disease. It is therefore necessary to explore novel agents for possible treatment of this tumor. Here the authors investigated the sensitivity of ES cells to clinically tolerable concentrations of arsenic trioxide (As2O3), a compound known to induce differentiation and apoptosis of other types of malignant cells. The authors report that As2O3 uniformly induced death of 6 ES-derived cell lines irrespective of their p53 status. As2O3 resulted in an apoptotic phenotype which was inhibited by the broad-spectrum caspase inhibitor ZVAD-fmk. These effects correlated with prolonged c-jun N-terminal kinase activation, which is a signal for apoptosis in ES cells. As2O3 also decreased basal and cytokine-induced NF-kappa B activity. Since the authors previously demonstrated that NF-kappa B exerts an antiapoptotic action in ES cells, As2O3 treatment may also result in a sensitization of these cells to other drugs used in combination...Continue Reading
References
Nov 24, 1995·Science·Z XiaM E Greenberg
Aug 4, 1994·The New England Journal of Medicine·O DelattreT J Triche
May 1, 1994·International Journal of Cancer. Journal International Du Cancer·R HamelinG Thomas
Mar 1, 1996·Molecular and Cellular Biology·U M MollG Zambetti
Mar 20, 1997·Oncogene·H YiE S Reddy
Dec 5, 1997·Hybridoma·T MelotO Delattre
Jul 23, 1999·Current Opinion in Oncology·H KovarA Zoubek
Jan 25, 2000·Oncogene·D JavelaudF Besançon
Sep 1, 2000·The Journal of Biological Chemistry·P KapahiM Karin
Jul 4, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C R PinkertonT Philip
Jul 24, 2001·Oncogene·D Javelaud, F Besançon
Aug 11, 2001·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Ann Bode, Zigang Dong
Oct 19, 2001·Oncogene·A Arvand, C T Denny
Feb 22, 2002·International Journal of Cancer. Journal International Du Cancer·Delphine JavelaudFrançoise Besançon
Sep 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E Anders KolbPaul A Meyers
Oct 31, 2003·Molecular and Cellular Biology·Vinay TergaonkarInder M Verma
Dec 10, 2003·Oncogene·Jérôme KucharczakCéline Gélinas
Jan 1, 2004·Blood·Kelly DavisonWilson H Miller
Jun 2, 2004·Pediatric Blood & Cancer·George ZogopoulosSheila Weitzman
Oct 16, 2004·Journal of Cell Science·Salvatore PapaGuido Franzoso
Jan 28, 2005·Oncogene·Christian ScholzPeter T Daniel
Sep 17, 2005·Molecular and Cellular Biology·Hon Kit WongAviva M Tolkovsky
Citations
Nov 12, 2013·Leukemia Research·Xiao-Hui ZhangX Long Zheng
Dec 18, 2007·Oncogene·J MathieuF Besançon
Dec 25, 2010·The Journal of Clinical Investigation·Elspeth M BeauchampAykut Uren
Jul 19, 2013·PloS One·Shunsuke NakamuraTakao Setoguchi
Sep 10, 2013·Surgical Oncology Clinics of North America·Derek J Erstad, James C Cusack
Jun 26, 2007·British Journal of Haematology·Richard A CampbellJames R Berenson
Apr 24, 2015·Frontiers in Oncology·Santiago Rello-VaronaOscar Martínez Tirado
Aug 16, 2016·Cancer Letters·Michael Torsten MeisterSimone Fulda
Dec 1, 2009·Melanoma Research·Valerie TrappJohn P Fruehauf
Jul 28, 2020·Pharmaceuticals·Angel Escamilla-RamírezCristina Trejo-Solís
Oct 26, 2016·International Journal of Oncology·Karen A BoehmeFrank Traub
Mar 15, 2018·Frontiers in Pharmacology·Mona DawoodThomas Efferth
Feb 27, 2021·Pediatric Hematology and Oncology·Michael AbeleMartin Ebinger
Nov 1, 2007·Chemical Research in Toxicology·Konstantin Salnikow, Anatoly Zhitkovich